Triochem Products

Mumbai, India Founded: 1972 • Age: 54 yrs Listed
Manufacturer and exporter of pharmaceutical bulk drugs and chemicals in India.

About Triochem Products

Triochem Products is a publicly listed company based in Mumbai (India) founded in 1972. Manufacturer and exporter of pharmaceutical bulk drugs and chemicals in India. It operates on a B2B model. The company has 10 employees. Its Indian entity Triochem Products Limited reported revenue of β‚Ή12.03 Cr. Triochem Products offers products and services including Pharmaceutical Bulk Drugs, APIs, and Chemicals. Its focus areas include Pharmaceuticals, Bulk Drugs and APIs and Chemicals. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.

Company details

Triochem Products Ltd., established in 1972, manufactures and exports pharmaceutical bulk drugs, APIs, and chemicals from India. Headed by Mr. Ramu S. Deora, it focuses on quality products at competitive prices with timely delivery to exceed client expectations. Operations are based in Mumbai and Ambernath, Maharashtra, serving global business partners.

  • Headquarters Mumbai, India
  • Employees 10
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website triochemproducts.com
  • Legal Name Triochem Products Limited
  • Date of Incorporation 07 Jan, 1972
  • Jurisdiction Mumbai, Maharashtra, India
Key Metrics
  • Market Cap
    ₹0.43 Cr

    TRIPR · BSE

  • Share Price
    ₹17.40

    0.00% today

  • EBITDA
    −₹1.36 Cr

    FY 2025-26

  • Net Profit
    −₹5.93 Cr

    FY 2025-26 · -597.7% YoY

  • ROE
    -34.6%

    ROCE -4.3%

  • Employee Count
    10

Products & Services of Triochem Products

Triochem Products offers a comprehensive portfolio of products and services, including Pharmaceutical Bulk Drugs, APIs, and Chemicals.

Pharmaceutical Bulk Drugs
Manufacturing

Production of bulk drugs for pharmaceutical applications

APIs
Chemical Manufacturing

Active ingredients used in pharmaceutical drugs

Chemicals
Industrial Chemicals

Various chemicals for export and industrial use

Board of directors of Triochem Products Limited (Triochem Products)

Triochem Products Limited is the primary company behind Triochem Products. The board of Triochem Products Limited currently have 6 directors; the longest-serving is Ramu Sitaram Deora, appointed in 1975. 4 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ramu Sitaram Deora
DIN 00312369
Director30 Jun 197551 yrs 4 moTriochem Products Limited
Shyam Sundar Sharma
DIN 01457322
Director28 May 198541 yrs 5 moTriochem Products Limited
Grace Ramu Deora
DIN 00312080
Director30 Mar 201511 yrs 7 moTriochem Products Limited
Rajesh Ramu Deora
DIN 00312316
Director28 May 20197 yrs 5 moTriochem Products Limited
Vipul Amul Desai
DIN 02074877
Director29 Mar 20251 yr 7 moTriochem Products Limited
Shailendra Mishra
DIN 07373830
Director29 Mar 20251 yr 7 moTriochem Products Limited

IPO & Listings of Triochem Products

Triochem Products is a publicly listed company on the BSE with ticker symbol TRIPR in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onBSE: TRIPR
  • Listed entityTriochem Products Limited
  • Exchange sectorPharmaceuticals

Financials of Triochem Products

Exchange-reported figures of Triochem Products Limited, the listed company behind Triochem Products (BSE: TRIPR).

Financial Highlights

FY 2025-26 Β· Standalone
Revenue
₹0.00 Cr
EBITDA
−₹1.36 Cr
-12.4% YoY
Profit After Tax
−₹5.93 Cr
-597.6% YoY
Net Worth
₹20.65 Cr
+51.1% YoY
Total Assets
₹20.65 Cr
+51.1% YoY
Total Debt
Nil

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue0.000.000.000.008.8213.9420.03
Revenue growth----100.0%-36.7%-30.4%-
EBITDA(1.36)(1.21)(2.27)(1.35)1.33(0.37)4.55
EBITDA margin----+15.1%-2.7%+22.7%
Profit before tax10.52(0.24)(1.33)(1.18)1.75(0.59)4.55
Net profit(5.93)(0.85)(0.12)(0.97)1.31(0.45)3.40
Net profit margin----+14.9%-3.2%+17.0%
EPS (β‚Ή)325.33(16.34)(41.36)(36.13)53.99(18.24)138.89
Balance sheet
Total assets20.6513.6714.6211.6013.0511.7114.68
Net worth20.6513.6714.6311.6013.0511.7212.18
Total debt0.000.000.000.000.000.002.50
Cash & bank11.730.910.540.9611.818.200.55
Net working capital12.962.312.451.0411.8310.6113.51
Cash flow
Cash from operations(2.87)0.20(3.76)(1.58)3.4710.253.82
Cash from investing13.700.173.34(9.27)0.160.00(0.03)
Cash from financing0.000.000.000.00(0.02)(2.61)(3.49)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue0.000.000.000.000.000.000.000.00
Other income0.170.1711.290.220.300.220.320.46
Total expenses0.060.040.220.380.420.360.330.59
EBITDA(0.06)(0.04)(0.22)(0.38)(0.42)(0.36)(0.33)(0.59)
Depreciation0.000.000.000.010.020.020.020.04
Interest0.000.000.080.000.000.000.000.00
Profit before tax0.110.1310.99(0.17)(0.14)(0.16)(0.03)(0.17)
Tax0.020.032.66(0.04)0.05(0.12)0.42(0.25)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 21 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue0.000.000.000.000.000.000.000.00
Other income0.170.1711.290.220.300.220.320.46
Total expenses0.060.040.220.380.420.360.330.59
EBITDA(0.06)(0.04)(0.22)(0.38)(0.42)(0.36)(0.33)(0.59)
Depreciation0.000.000.000.010.020.020.020.04
Interest0.000.000.080.000.000.000.000.00
Profit before tax0.110.1310.99(0.17)(0.14)(0.16)(0.03)(0.17)
Tax0.020.032.66(0.04)0.05(0.12)0.42(0.25)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue0.000.000.000.008.8213.9420.03
Revenue growth----100.0%-36.7%-30.4%-
Other income12.031.051.030.280.560.130.47
Total expenses1.361.212.271.357.4914.3115.48
Employee cost0.530.590.470.520.500.670.82
EBITDA(1.36)(1.21)(2.27)(1.35)1.33(0.37)4.55
EBITDA margin----+15.1%-2.7%+22.7%
Depreciation0.050.080.090.110.120.140.17
Interest0.100.000.000.000.020.210.30
Profit before tax10.52(0.24)(1.33)(1.18)1.75(0.59)4.55
Tax2.540.15(0.32)(0.29)0.44(0.14)1.15
Net profit(5.93)(0.85)(0.12)(0.97)1.31(0.45)3.40
Net profit margin----+14.9%-3.2%+17.0%
EPS (β‚Ή)325.33(16.34)(41.36)(36.13)53.99(18.24)138.89
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital0.250.250.250.250.250.250.25
Reserves & surplus20.4013.4214.3811.3512.8011.4711.93
Shareholders' funds (net worth)20.6513.6714.6311.6013.0511.7212.18
Secured loans0.000.000.000.000.000.001.25
Unsecured loans0.000.000.000.000.000.001.25
Total debt0.000.000.000.000.000.002.50
Total liabilities20.6513.6714.6211.6013.0511.7114.68
Assets
Gross block0.002.032.032.032.021.971.95
Net block0.000.600.680.770.870.941.06
Capital work in progress0.000.000.000.000.000.030.03
Investments7.8910.6311.079.420.000.000.00
Inventories0.000.000.050.050.050.851.55
Sundry debtors0.000.000.000.000.001.3912.40
Cash & bank balances11.730.910.540.9611.818.200.55
Loans & advances1.261.622.130.270.180.560.86
Total current assets12.992.532.721.2812.0411.0015.36
Total current liabilities0.030.220.270.240.210.391.85
Net working capital12.962.312.451.0411.8310.6113.51
Total assets20.6513.6714.6211.6013.0511.7114.68
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.910.540.9611.818.200.550.25
Net cash from operating activities(2.87)0.20(3.76)(1.58)3.4710.253.82
Net cash from investing activities13.700.173.34(9.27)0.160.00(0.03)
Net cash from financing activities0.000.000.000.00(0.02)(2.61)(3.49)
Net change in cash10.820.37(0.42)(10.85)3.617.640.30
Closing cash11.730.910.540.9611.818.200.55
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth----100.0%-36.7%-30.4%-
EBITDA growth-12.4%+46.7%-68.2%-201.5%+459.5%-108.1%-
PBT growth+9998.0%+82.0%-12.7%-+9998.0%-+333.3%
Net income growth-597.7%-608.3%+87.6%-174.1%+391.1%-113.2%-
Revenue CAGR (3Y)--100.0%-100.0%-100.0%-10.6%-26.4%+3.5%
EBITDA CAGR (3Y)+0.3%-+83.1%--7.1%-+66.3%
Profitability & leverage
Net income margin----+14.9%-3.2%+17.0%
Return on capital employed-4.3%-3.3%-2.7%-9.5%+14.4%-2.8%+33.2%
Return on net worth-34.6%-6.1%-0.9%-7.2%+10.7%-3.8%+32.4%
Debt / equity0.000.000.000.000.000.100.40
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover-7.090.000.000.001.65-41.186.85
Efficiency & per share
Fixed asset turnover0.000.000.000.004.427.1110.27
Inventory turnover0.000.000.000.0019.6011.623.60
Debtors turnover0.000.000.000.0012.692.022.55
EPS (β‚Ή)325.33(16.34)(41.36)(36.13)53.99(18.24)138.89
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)842.78557.83596.74473.36532.51478.04497.00

Similar companies to Triochem Products

Triochem Products has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
lauruslabs.com2005Hyderabad, India$229.73M6,035
Pharmaceutical and biotechnology company
symbiotec.in2002Indore, India$61.01M1,822
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
sequent.in2002Bengaluru, India
APIs are developed and manufactured for therapeutic areas.
Premium access

Detailed similar companies of Triochem Products

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Triochem Products

Premium access

Complete news archive for Triochem Products

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Triochem Products

Triochem Products was founded in 1972.

Triochem Products is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Triochem Products has 10 employees.

The primary company behind Triochem Products, Triochem Products Limited, reported revenue of β‚Ή12.03 Cr for FY 2026, up 9997% year on year.

Triochem Products Ltd., established in 1972, manufactures and exports pharmaceutical bulk drugs, APIs, and chemicals from India. Headed by Mr. Ramu S. Deora, it focuses on quality products at competitive prices with timely delivery to exceed client expectations. Operations are based in Mumbai and Ambernath, Maharashtra, serving global business partners.

Triochem Products's top competitors include Laurus Labs, Symbiotec and SeQuent.

Triochem Products offers Pharmaceutical Bulk Drugs, APIs, and Chemicals.

Yes, Triochem Products is publicly traded on BSE under the ticker symbol TRIPR.

Triochem Products operates through Triochem Products Limited.

The legal entities of Triochem Products currently have 8 directors, including Grace Ramu Deora, Ramu Sitaram Deora, Shyam Sundar Sharma and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available